Quick Answer
Liminatus Pharma, Inc. reported Stockholders Equity of -$9.81 million for fiscal year 2025.
Liminatus Pharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$9.81M | +49.3% |
| 2024 | -$19.34M | -22.5% |
| 2023 | -$15.79M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.65M | +91.4% | +81.3% |
| June 30, 2025 | -$8.81M | +52.4% | +55.2% |
| March 31, 2025 | -$19.67M | -12.1% | -1.7% |
| December 31, 2024 | -$19.34M | -22.5% | -1.2% |
| September 30, 2024 | -$19.11M | — | -3.2% |
| June 30, 2024 | -$18.51M | — | -5.5% |
| March 31, 2024 | -$17.55M | — | -11.1% |
| December 31, 2023 | -$15.79M | — | — |
- Liminatus Pharma, Inc. showed an increase of +49.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2023–2025 period, Liminatus Pharma, Inc.’s stockholders equity has grown by 37.9% (from -$15.79 million to -$9.81 million).
- The most recent figure is from Liminatus Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: